Cipla announces JV with Kemwell Biopharma and Manipal Group for cell therapy development
Cipla (EU) Limited, UK, a wholly-owned subsidiary of Cipla Limited, has entered into a strategic collaboration with Kemwell Biopharma Private Limited and Manipal Education & Medical Group, marking the inception of a joint venture in the United States. This alliance aims to develop and commercialize novel cell therapy products, addressing major unmet medical needs in the United States, Japan, and EU regions.
Joint Venture Composition and Investment Focus
Cipla (EU) Limited will acquire a significant 35.2% stake in the new joint venture company. The collaboration leverages Cipla’s strengths in product development and commercialization, Kemwell Biopharma’s expertise in biologics, and Manipal Group’s prowess in healthcare delivery. The joint venture is primarily focused on expediting the development and global distribution of cutting-edge cell therapy products.
Leadership Insights on the Collaboration
Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, emphasized the venture’s commitment to advancing transformative treatments in stem cell and CAR T-cell therapies. He highlighted the partnership’s potential to make a global impact on patient lives through innovative biotech and cell-engineering research.
Strategic Alliance: Cipla to Develop Novel Cell Therapies with Kemwell and Manipal Group
Dr. Ranjan Pai, Chairman of Manipal Education & Medical Group, expressed optimism about the venture’s ability to bring advanced biological therapies to the global market, particularly in addressing serious medical conditions. Anurag Bagaria, Chairman and CEO of Kemwell, noted the potential of cell therapies in becoming a standard of care for challenging diseases and transforming global health treatments.
Previous Successful Joint Venture Between Cipla and Kemwell Biopharma
This is not the first collaboration between Cipla and Kemwell Biopharma. They previously formed Aspergen Inc., USA, in 2022, focusing on the development and commercialization of biosimilars for global markets. This venture is actively developing two projects, reinforcing Cipla’s lung leadership agenda and strengthening its position in the biosimilar market.
The joint venture between Cipla, Kemwell Biopharma, and Manipal Group represents a significant step in biopharmaceutical innovation, highlighting a concerted effort to develop and bring to market groundbreaking cell therapies. This strategic move aligns with the global healthcare trend towards advanced, personalized treatments.